Overview

Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients after operation.
Phase:
Phase 1
Details
Lead Sponsor:
Eastern Hepatobiliary Surgery Hospital
Treatments:
Everolimus
Sirolimus